Compare Enact Holdings Inc (ACT) vs Danaher Corporation (DHR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Enact Holdings Inc vs Danaher Corporation — how do they compare? Enact Holdings Inc trades at $45.17 (market cap $6.35B), while Danaher Corporation trades at $190.64 (market cap $137.44B). The key difference: Danaher Corporation is far larger — about 21.6× Enact Holdings Inc's market cap, and Enact Holdings Inc pays the higher dividend (1.91%). Which is the better fit depends on your goals.
| ACT | DHR | |
|---|---|---|
Market Cap | $6.35B | $137.44B |
Sector | Technology | Health |
52-Week High | $45.71 | $242.05 |
52-Week Low | $34.39 | $161.91 |
Enterprise Value | $6.55B | $150.22B |
Dividend Yield | 1.91% | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACT trades at $45.69, up 0.77% today, with a bullish technical signal and strong moving averages. The stock shows robust fundamentals with a net income margin of 54.49% and a P/E ratio of 9.89. Recent news includes a 14% dividend increase announced on May 5, 2026, and Q1 2026 earnings that met expectations. Analyst consensus is a $47.50 price target with a mix of buy and hold ratings.
Outlook remains positive due to high profitability and dividend growth, but risks include earnings volatility and market sensitivity. Upside is supported by institutional sentiment and consistent cash flow, though investors should monitor execution against future earnings estimates.
Danaher (DHR) trades at $193.62, down 2.18% today but remains in a bullish technical trend with strong support near $190. The company demonstrates solid fundamentals with a 58.94% gross margin and consistent earnings beats in recent quarters. Recent news highlights strategic collaborations and a pending acquisition of Masimo, approved by shareholders in May 2026, signaling growth initiatives.
The outlook is positive with a consensus price target of $214.73, implying 11% upside. Key risks include revenue stagnation and a high P/E ratio of 37.52. Analyst sentiment is strongly bullish (69% buy ratings), but investors should monitor execution on acquisitions and bioprocessing demand trends for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enact Holdings Inc
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
